Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
23.25
-0.70 (-2.92%)
Oct 16, 2026, 4:00 PM EDT - Market closed
Neurogene Market Cap
Neurogene has a market cap or net worth of $465.26 million as of October 16, 2026. It is the 15,186th most valuable company in the world and the 2,776th biggest in the United States. Its market cap has decreased by 5.15% in one year.
Market Cap
465.26M
Enterprise Value
248.22M
1-Year Change
-5.15%
Global Rank
Country Rank
#2,776 United States
Category
ChartMarket Cap Chart
Since December 19, 2023, Neurogene's market cap has increased from $193.64M to $465.26M, an increase of 140.28%. That is a compound annual growth rate of 36.35%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 16, 2026 | 465.26M | 45.81% |
| Dec 31, 2025 | 319.09M | -6.03% |
| Dec 31, 2024 | 339.58M | 36.64% |
| Dec 29, 2023 | 248.52M | 28.34% |
| Dec 19, 2023 | 193.64M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| CytomX Therapeutics | 496.81M |
| Faeth Therapeutics | 485.80M |
| Aclaris Therapeutics | 482.81M |
| Entera Bio | 466.11M |
| Monopar Therapeutics | 464.95M |
| REGENXBIO | 457.14M |
| Arvinas | 455.74M |
| Allogene Therapeutics | 452.59M |